secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001437749-25-032422
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Therapeutics Q3 net loss $12.8M, cash $182.4M, pipeline milestones affirmed
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $182.4M; projected cash runway extended through 2028.
- Net loss $12.8M vs $10.3M in prior-year quarter; R&D expenses $11.0M (+13% YoY).
- Generated $19.0M from ATM offerings of 3.2M shares at weighted avg $6.04/share.
- Topline data from PIPE-307 Phase 2 VISTA RRMS trial expected Q4 2025; global Phase 2 for PIPE-791 IPF to initiate Q4 2025.
- Deferred initiation of PIPE-791 PrMS and CTX-343 trials to extend cash runway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925032422/0001437749-25-032422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925032422/ctnm20251015_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-032422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer